Alzheimer’s drug reduces plaques, slows disease progression: full results

Alzheimer’s drug reduces plaques, slows disease progression: full results

The monoclonal antibody donanemab slows clinical progression among patients with early symptomatic Alzheimer’s disease by up to a third compared to placebo, according to a study in JAMA. … [read more]

Related News Stories:

  1. Fructose Linked to Alzheimer’s: Study
  2. Higher urine-to-plasma urea ratio reflects heightened risk of chronic kidney disease (CKD) progression
  3. Long COVID is defined by these 12 symptoms, new study finds
  4. This highly infectious disease is similar to Ebola, but what is Marburg virus disease? Is there a vaccine?
  5. COVID-19 pandemic ‘still with us’ for patients with autoimmune, inflammatory diseases
  6. COVID-19 vaccine effective against hospitalization from Omicron variant
  7. Daily Calf Stretching Can Alleviate Pain, Help Patients Avoid Foot and Ankle Surgery
  8. Substances in Urine and Blood Predict Kidney Disease Progression
  9. Mushrooms Magnify Memory by Boosting Nerve Growth
  10. AGA Releases Guidelines on Use of Fecal and Blood Tests for Monitoring Ulcerative Colitis
Find Weird and Wonderful Books at AbeBooks
Study on cause of Alzheimer’s turns established theory on its head

Study on cause of Alzheimer’s turns established theory on its head

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Eating traditional Mediterranean-type diet may help reduce dementia risk

Eating traditional Mediterranean-type diet may help reduce dementia risk

Fructose Linked to Alzheimer’s: Study

Fructose Linked to Alzheimer’s: Study

Mushrooms Magnify Memory by Boosting Nerve Growth

Mushrooms Magnify Memory by Boosting Nerve Growth

Leave a Reply

Your email address will not be published. Required fields are marked *